Drug Trial Radar · NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Nov 30, 2029
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Brian RiniAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals; Vanderbilt-Ingram Cancer Center
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
Conditions
- Advanced Renal Cell Carcinoma (aRCC)
- Metastatic Renal Cell Carcinoma ( mRCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
FianlimabDrug
Fianlimab will be co-administered by IV.
IpilimumabDrug
Ipilimumab will be administered by IV.
NivolumabDrug
Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
CemiplimabDrug
Cemiplimab will co-administered by IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Georgetown University
Washington D.C., District of Columbia · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Penn State Cancer Institute
Hershey, Pennsylvania · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.